Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $32.74 USD
Change Today -0.47 / -1.42%
Volume 78.5K
PAHC On Other Exchanges
Symbol
Exchange
NASDAQ GM
As of 8:10 PM 04/27/15 All times are local (Market data is delayed by at least 15 minutes).

phibro animal health corp-a (PAHC) Snapshot

Open
$33.26
Previous Close
$33.21
Day High
$33.76
Day Low
$32.50
52 Week High
02/25/15 - $37.56
52 Week Low
05/14/14 - $16.54
Market Cap
1.3B
Average Volume 10 Days
138.7K
EPS TTM
$1.26
Shares Outstanding
17.5M
EX-Date
03/2/15
P/E TM
25.9x
Dividend
$0.40
Dividend Yield
0.92%
Current Stock Chart for PHIBRO ANIMAL HEALTH CORP-A (PAHC)

Related News

No related news articles were found.

phibro animal health corp-a (PAHC) Related Businessweek News

No Related Businessweek News Found

phibro animal health corp-a (PAHC) Details

Phibro Animal Health Corporation operates as a diversified developer, manufacturer, and marketer of a range of animal health and mineral nutrition products for use in the production of poultry, swine, cattle, dairy, and aquaculture. It also sells specialty ingredients for use in the personal care, automotive, industrial chemical, and chemical catalyst industries. The company operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The Animal Health segment offers antibacterials, anticoccidials, and vaccines, which help prevent and manage infectious diseases in livestock and enhance food safety; and nutritional specialty products, which aid the continued health of livestock by enhancing nutrition to help improve health and performance. The Mineral Nutrition segment manufactures and markets approximately 450 formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron, and other compounds, with a focus on customers in North America. The Performance Products segment manufactures and markets various specialty ingredients for use in the personal care, automotive, industrial chemical, and chemical catalyst industries, primarily in the United States. The company sells its animal health and mineral nutrition products through local sales offices either directly to integrated poultry, swine, and cattle integrators; or through commercial animal feed manufacturers, wholesalers, and distributors. It sells its performance products through local sales offices to the personal care, automotive, industrial chemical, and chemical catalyst industries. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation is headquartered in Teaneck, New Jersey.

1,100 Employees
Last Reported Date: 09/18/14

phibro animal health corp-a (PAHC) Top Compensated Officers

Chairman, Chief Executive Officer, President,...
Total Annual Compensation: $3.0M
Chief Operating Officer and Director
Total Annual Compensation: $914.7K
President of Animal Health
Total Annual Compensation: $708.5K
Compensation as of Fiscal Year 2014.

phibro animal health corp-a (PAHC) Key Developments

Phibro Animal Health Corporation Announces Unaudited Consolidated Earnings Results for Fourth Quarter and Full Year Ended Dec. 31, 2014

Phibro Animal Health Corporation announced unaudited consolidated earnings results for fourth quarter and full year ended Dec. 31, 2014. For the quarter, the company reported net sales of $188.7 million, operating income of $19.8 million, income before income taxes of $17.3 million, net income of $15.4 million or $0.39 per diluted share, adjusted EBITDA of $25 million, adjusted net income of $14.1 million or $0.33 per diluted share, net cash provided by operating activities of $8.4 million compared to the net sales of $172.7 million, operating income of $17 million, income before income taxes of $7.1 million, net income of $2.3 million or $0.08 per diluted share, adjusted EBITDA of $22.3 million, adjusted net income of $13.6 million or $0.34 per diluted share, net cash provided by operating activities of $16.6 million for the same quarter a year ago. Net sales increased $15.9 million, or 9%, as compared to the three months ended December 31, 2013, due to growth in Animal Health and Mineral Nutrition of $10.8 million and $8.1 million, respectively, offset by declines in Performance Products of $3.0 million. For the year, the company reported net sales of $376.1 million, operating income of $44.9 million, income before income taxes of $40.1 million, net income of $35.9 million or $0.9 per diluted share, adjusted EBITDA of $55.5 million, adjusted net income of $34.4 million or $0.87 per diluted share, net cash provided by operating activities of $25.8 million compared to the net sales of $335 million, operating income of $33.4 million, income before income taxes of $14.1 million, net income of $8.1 million or $0.27 per diluted share, adjusted EBITDA of $43.9 million, adjusted net income of $25.3 million or $0.64 per diluted share, net cash provided by operating activities of $16.4 million for the previous year.

Phibro Animal Health Corporation Declares Quarterly Cash Dividend, Payable on March 25, 2015

Phibro Animal Health Corporation announced the declaration of a quarterly cash dividend of $0.10 per share on its Class A common stock and Class B common stock, payable on March 25, 2015, to stockholders of record at the close of business on March 4, 2015.

Phibro Animal Health Corporation Announces Licensing Agreement with Merial for Phibro's Vaccine Delivery Technology

Phibro Animal Health Corporation announced it has entered into a long-term global license arrangement with Merial SAS (Lyon, France) to share in the use of Phibro's vaccine delivery technology for use in animal vaccines. The agreement was signed in 2012 and is being announced following Merial's receipt of marketing authorization in France for an avian vaccine product utilizing the licensed technology. The patented technology utilizes an innovative effervescent tablet that contains a freeze-dried sterile vaccine virus, packaged in sealed aluminum blister packages. The technology replaces the glass vials that are in common use today, and offers major advantages in a number of areas including storage requirements, customer handling and disposal. Under the arrangement, use of the technology will be limited to Merial, Phibro and their affiliates.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PAHC:US $32.74 USD -0.47

PAHC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Bayer AG €137.72 EUR +2.53
Novartis AG SFr.100.40 CHF +0.60
Virbac SA €239.10 EUR +2.25
Zoetis Inc $46.83 USD -1.08
View Industry Companies
 

Industry Analysis

PAHC

Industry Average

Valuation PAHC Industry Range
Price/Earnings 49.7x
Price/Sales 1.8x
Price/Book 49.7x
Price/Cash Flow 44.5x
TEV/Sales 1.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PHIBRO ANIMAL HEALTH CORP-A, please visit www.pahc.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.